DC STEM Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on DC STEM Digest.

Press releases published on April 22, 2026

Apr. 22, 2026

New Biometric Data Standards Released

Indeterminate EIN Presswire

Apr. 22, 2026

Protego Systems Launches 500 Series TAA-Compliant USB Desk Phone - a Secure, Headset-Free Alternative for Softphone Use

Indeterminate EIN Presswire

Apr. 22, 2026

Vijay Vijayasankar Explains The Rise of Agentic AI in the CAIO Connect Podcast with Sanjay Puri

Indeterminate EIN Presswire

Apr. 22, 2026

Dunlap Bennett & Ludwig Partner Alex Butterman to Moderate Key Session at the 2026 INTA Annual Meeting in London

Indeterminate EIN Presswire

Apr. 22, 2026

aiComply Launches NavigateCyber Financial Services to Support Banks Transitioning from FFIEC CAT to NIST CSF 2.0

Indeterminate EIN Presswire

Apr. 22, 2026

PolicyOra Data Reveals Rising Compliance Pressure on Enterprise Legal Teams as AI Governance Gaps Widen

Indeterminate EIN Presswire

Apr. 22, 2026

Homesage.ai Launches Rental Market Intelligence for Airbnb Investors

Indeterminate EIN Presswire

Apr. 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Indeterminate GlobeNewswire

Apr. 22, 2026

The Elmet Group Co. Announces Pricing of Upsized Initial Public Offering

Indeterminate GlobeNewswire

Apr. 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Indeterminate GlobeNewswire

Apr. 22, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Indeterminate GlobeNewswire

Apr. 22, 2026

 nCino Announces Nick Edwards as Managing Director for APAC

Indeterminate GlobeNewswire

Apr. 22, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire

Apr. 22, 2026

Kneat to Announce 2026 First-Quarter Financial Results May 13, 2026

Indeterminate GlobeNewswire

Apr. 22, 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Indeterminate GlobeNewswire

Apr. 22, 2026

GigaCloud Technology Inc Announces Planned Retirement of Head of Brand Center

Indeterminate GlobeNewswire

Apr. 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Indeterminate GlobeNewswire

Apr. 22, 2026

BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-K Filing

Indeterminate GlobeNewswire

Apr. 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 22, 2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

Indeterminate GlobeNewswire